PACAP and NAP: Effect of Two Functionally Related Peptides in Diabetic Retinopathy

J Mol Neurosci. 2021 Aug;71(8):1525-1535. doi: 10.1007/s12031-020-01769-4. Epub 2021 Jan 5.

Abstract

Pituitary adenylate cyclase-activating polypeptide (PACAP) is a peptide involved in physio-pathological processes of the eye. It exerts multiple effects directly through activation of its related receptors and indirectly through increases in the synthesis of activity-dependent neuroprotective protein (ADNP). To study the role of ADNP and protect against ADNP deficiencies, a small peptide called NAP was synthetized. It includes an eight amino acid active site sequence of ADNP. In this review, we summarize the knowledge regarding the neuroprotective function played by PACAP and NAP in retinal tissue and provide an overview of the correlation between PACAP and ADNP in the context of diabetic retinopathy.

Keywords: ADNP; Diabetic retinopathy; Hyperglycemia; NAP; PACAP.

Publication types

  • Review

MeSH terms

  • Animals
  • Diabetic Retinopathy / metabolism*
  • Humans
  • Neuroprotective Agents / metabolism
  • Neuroprotective Agents / pharmacology
  • Oligopeptides / metabolism
  • Oligopeptides / pharmacology*
  • Pituitary Adenylate Cyclase-Activating Polypeptide / metabolism
  • Pituitary Adenylate Cyclase-Activating Polypeptide / pharmacology*
  • Retina / drug effects
  • Retina / metabolism

Substances

  • Neuroprotective Agents
  • Oligopeptides
  • Pituitary Adenylate Cyclase-Activating Polypeptide
  • davunetide